A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2017
At a glance
- Drugs NA 1 (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ESCAPE-NA1
- Sponsors NoNO
- 27 Feb 2017 Status changed from not yet recruiting to recruiting, according to a NoNO media release.
- 27 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.
- 13 Oct 2016 New trial record